The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead (GILD) announced The New England Journal of Medicine, or NEJM, published the full results from the company’s pivotal Phase 3 PURPOSE 2 ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) on November 25 and set a price target ...

A vaccination with the drug lenacapavir offers an effective protection against a HIV infection, according to newly published ...

Global HIV rates drop 20 but challenges persist in ending AIDS by 2030 Explore breakthroughs like lenacapavir prevention ...

While oral PrEP is effective in curbing the risk of HIV infection, it needs to be followed consistently every day for ...

Corkscrew is coming home to Lake Norman. The longtime wine bar has inked a deal for an 1,800-square-foot space in ...

Expect scattered rain showers. The low will be 66°. Moderate air quality (51-100) Primary pollutant O₃ 86 μg/m³ Amount of moisture present in the air relative to the maximum amount of moisture the air ...

This week's Richland County Girls Basketball Power Poll didn't change a whole lot, but there was some movement.

In addition, we kept open the possibility that the ETF will continue to rise and could reach around 108.45. To see how we ...